Rhino Propels Federated AI into the Enterprise Tech Stack
Opening Bell Ventures Launches Shelly, the AI Knowledge Worker That Checks What People Say Against What the Data Shows
Peec AI launches Peec Agent and expands actions so marketing teams can act on what AI search says about their brand
CPAClub Announces New Annual Pass to Help Law Firms Stay Ahead of CTAPP Compliance and Save on Review Costs
Purple goes live across Derbion with Engage
Preclinical data with APG777 demonstrate the potential for significantly improved dosing over standard of care,…
SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage…
SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage…
— Announced full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and…
— Announced full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and…
— VAZKEPA® (icosapent ethyl) accepted by the Scottish Medicines Consortium (SMC) for restricted use within…
— VAZKEPA® (icosapent ethyl) accepted by the Scottish Medicines Consortium (SMC) for restricted use within…
– Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced;…
– Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced;…
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Arbor Biotechnologies®, a biotechnology company discovering and…
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) — Arbor Biotechnologies®, a biotechnology company discovering and…
Topline Results Expected Third Quarter 2023 Long COVID Afflicts Approximately 19% of Patients Following COVID-191,…
Topline Results Expected Third Quarter 2023 Long COVID Afflicts Approximately 19% of Patients Following COVID-191,…
Ikena receives approximately $43 million in net cash at closing New capital will further accelerate…
Ikena receives approximately $43 million in net cash at closing New capital will further accelerate…
Composite qEEG measure showed change from placebo after first dose of 5 mg Effect in…
Composite qEEG measure showed change from placebo after first dose of 5 mg Effect in…
– First patient dosed in phase 1/2 trial of TNG462, a next-generation PRMT5 inhibitor for…
– First patient dosed in phase 1/2 trial of TNG462, a next-generation PRMT5 inhibitor for…
EMERYVILLE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage…